Welcome to our dedicated page for Evolent Health SEC filings (Ticker: EVH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Evolent Health, Inc. (NYSE: EVH) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K, annual and quarterly reports, and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Evolent’s specialty care business, capital structure, governance and material events affecting the company.
Through its 8-K filings, Evolent reports results of operations and financial condition, such as quarterly earnings releases that include revenue and adjusted EBITDA, explanations of non-GAAP financial measures and management’s discussion of demand for complex specialty care solutions. Other 8-Ks describe capital markets and financing activities, including the issuance of 4.50% convertible senior notes due 2031, the related indenture terms, and the use of proceeds to repurchase 1.50% convertible senior notes due 2025 and shares of Class A common stock. Amendments to credit agreements and commitment letters for incremental facilities are also disclosed, outlining available debt capital and key conditions.
Evolent’s filings further cover strategic transactions, such as the stock purchase agreement to sell its value-based primary care business, Evolent Care Partners, to Privia Management Company, LLC, and subsequent filings noting consummation of that transaction. Governance and leadership changes are documented under Item 5.02 of Form 8-K, detailing appointments and transitions in executive roles, including the Chief Financial Officer, as well as board retirements and new independent director appointments and related compensation and indemnification arrangements.
Regulatory and legal matters appear in filings as well. For example, Evolent has disclosed receiving a Civil Investigative Demand from the Department of Justice in connection with a False Claims Act investigation related to a former customer and Medicare Advantage diagnosis codes, and has stated that it is cooperating with the government.
On Stock Titan, these filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the implications of earnings releases, financing agreements, strategic transactions, leadership changes and legal disclosures. Real-time updates from EDGAR ensure that new 8-Ks, 10-Qs, 10-Ks and other forms are available promptly, while structured access to information on insider and executive arrangements can support deeper analysis of Evolent’s corporate governance and compensation practices.
Key takeaways from Evolent Health (EVH) Form 4
Chief Financial Officer John Paul Johnson was granted 25,461 Class A restricted stock units (RSUs) on 1 July 2025 under the company’s Amended and Restated 2015 Omnibus Incentive Compensation Plan. The award was made at no cost (Transaction Code “A”) and increases his directly held stake to 309,245 shares.
The RSUs vest on a back-loaded schedule: 34 % on 1 July 2026 and 33 % on each of 1 July 2027 and 1 July 2028. This tranche represents the second portion of the 2025 annual equity cycle; issuance was contingent on shareholder approval of additional plan shares received at the 5 June 2025 annual meeting.
No open-market purchases, derivative transactions or sales were disclosed, and no earnings or cash proceeds are involved. The filing is therefore routine incentive compensation that strengthens executive equity alignment but has minimal direct financial impact on near-term valuation.
Evolent Health (EVH) said on June 19, 2025 that oncology cost trends through May remain below its expectations, and the company reaffirmed full-year 2025 Adjusted EBITDA guidance of $135.0 million to $165.0 million and Q2 2025 Adjusted EBITDA guidance of $33.0 million to $40.0 million. The company stated it cannot meaningfully reconcile this non-GAAP guidance to net income because several significant reconciling items are not presently determinable. Separately, on June 19 the company and EVH LLC entered a Commitment Letter with Ares Management credit funds for an incremental debt facility to provide non-dilutive capital to retire its 2025 Convertible Notes by October 15, 2025 and to fund working capital, with a post-payoff cash target of no more than $125.0 million.